Sustained virologic response after antiviral therapy for recurrent Hepatitis C virus infection in liver transplant recipients is consistently lower than that achieved in non- liver transplant patients.
Dr Anna Lok and colleagues from Michigan, USA evaluated efficacy and safety of pegylated interferon and ribavirin therapy in liver transplant recipients with recurrent Hepatitis C and factors associated with sustained virologic response.
All subjects with histologic evidence of recurrent Hepatitis C were intended to be treated for 48 weeks with full-dose pegylated interferon.
The target dose of ribavirin was 800 mg/day.
|Sustained virologic response was achieved in 37% of patients|
The team assessed 35 liver transplant recipients with recurrent Hepatitis C, and a median age of 49 years treated between 2000 and 2006.
Of these patients, 77% were genotype 1 with a median pretreatment Hepatitis C virus RNA 6.4 log10 IU/mL.
Antiviral therapy was discontinued prematurely in 15 subjects as a result of adverse events.
Median overall treatment duration was 46 weeks.
The research team observed early virologic response at week in 49%, and an end-of-treatment virological response in 54% of patients.
The team noted that sustained virologic response was achieved in 37% of patients.
All 9 patients followed for more than 1 year after treatment had durable response.
The researchers found that patients with sustained virologic response had significantly lower pretreatment Hepatitis C virus RNA.
The team also noted that patients with sustained virologic response were more likely to have a week 12 virological response vs patients who did not respond to treatment.
In addition, patients with sustained virologic response received higher cumulative doses of pegylated interferon and ribavirin vs those who did not respond to therapy.
Dr Lok's concludes, "Sustained virologic response was achieved in 37% of patients with recurrent Hepatitis C after liver transplant."
"Similar to non- liver transplant patients, those with lower pretreatment Hepatitis C virus RNA, a week 12 virological response, and pegylated interferon and ribavirin dose adherence were more likely to achieve sustained virologic response."